Carrier screening is generally performed for inherited diseases in which both parents must be carriers as to have an affected child. Carrier screening finds out whether or not an individual carries a change in one of their genes and if they are at high risk of having a child affected with an inherited disease. Everyone pass on abnormal genes, and in common, carriers have no symptoms or signs of the disease they carry. The increase in the occurrence of inherited and chromosomal diseases such as fragile x syndrome, alpha thalassemia, spinal muscular atrophy, cystic fibrosis, and several others and the increase in technological advancement for the development of the advanced carrier screening kits and devices fuels the growth of the U.S. carrier screening market. On the other hand, the limited skilled professionals and dearth of standard guidelines for carrier screening are the factors restraining the U.S. Carrier Screening market growth. The U.S. Carrier Screening Market is projected to grow at a rate of 14.1% CAGR by 2027.

U.S. Carrier Screening Market on the basis of Type

• Expanded Carrier Screening
• Customized Panel Testing
• Predesigned Panel Testing
• Targeted Disease Carrier Screening

U.S. Carrier Screening Market on the basis of Technology

• DNA Sequencing
• Polymerase Chain Reaction
• Microarrays
• Others

U.S. Carrier Screening Market on the basis of End User

• Hospitals & Clinics
• Reference Laboratories
• Physician Offices
• Others

On the basis of type, the U.S. Carrier Screening market is divided into Expanded Carrier Screening and Targeted Disease Carrier Screening. The expanded carrier screening is likely to hold the maximum share in the market growth. The expanded carrier screening is further divided into Customized Panel Testing and Predesigned Panel Testing. Since, the ECS is the rising carrier screening type as it considers a wide technique by screening for various genetic disorders regardless of ethnic background. Companies in the market are indulging in strategic initiatives such as product development to increase their market share.

In the market based on technology, the U.S. Carrier Screening market is segmented into Polymerase Chain Reaction, Microarrays DNA Sequencing, and Others. DNA Sequencing segment holds the highest share in the market. This is owing to the advantages of the DNA Sequencing such as precise accuracy is one of the key factors which define the usefulness of a genetic carrier testing workflow in a clinical laboratory fuels the growth of the market. Moreover, various prenatal diagnostics clinics integrate sequencing technology in the carrier screening tests due to their advantages.

Based on the End User, the U.S. Carrier Screening market is categorized into Hospitals & Clinics, Reference Laboratories, Physician Offices and Others. The Hospitals & Clinics segment holds the substantial share of the Carrier Screening market. This is due to the developing healthcare facilities; facilities for medical and surgical treatment as well as nursing care to patients, physical rehabilitation post surgeries, and the availability of advanced equipment are the major aspects which accelerate the growth of the market in the forecasted years.

Apart from this, the surge in the increasing demand for the early detection of genetic disorders among the population and broad access to advanced screening techniques accelerates the growth of the U.S market. The rise of the U.S. carrier screening market is projected to be driven by the increase in awareness regarding the prominence of early detection of genetic disorders, and a surge in the demand for tele consultancy services. In addition, the rise in the number of R&D activities in the area of carrier screening kits or medical devices improved healthcare services, and extensive investments by the government to enhance healthcare infrastructure has become significant tool for small and large businesses which fuel the growth of the market.

Key players operating in the market include Myriad Genetics Inc., Thermo Fisher Scientific Inc., PerkinElmer Inc., Fulgent Genetics Inc., Quest Diagnostics Incorporated, Invitae Corporation, Illumina Inc., Natera Inc., LabCorp, and Sema4.

Genetic disease is the major cause of infant death in the United States, accounting for around 20% of annual infant mortality. Therefore, the wide implementation of screening programs has majorly reduced the incidence of genetic disease in the country among infants.

• This report elucidates how the various attributes are impacting the S. carrier screening market growth in the forecasted time span.
• This research provides thorough analysis of the segments and sub segments of the market and their key contributions in the market growth.
• This report comprises of the exclusive depiction of the competitive outlook coupled with key strategies deployed by the market competitors.